Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

918.90 -17.10 (-1.83%)
Delayed Quote Updated: 3:48 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
From argenx SE
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
A Look Into argenx Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls ↗
FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease. 
Via Benzinga
News headline image
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
From argenx SE
Via GlobeNewswire
News headline image
Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention ↗
VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
News headline image
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? ↗
HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027. 
Via Benzinga
News headline image
This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
Via Benzinga
News headline image
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
14 Analysts Have This To Say About argenx ↗
 
Via Benzinga
News headline image
Argenx Shares Drop After Q1 Miss, But Retail Traders Call Sub-$550 ‘An Absolute Steal’ ↗
Despite the Q1 miss, management reiterated confidence in its long-term “Vision 2030” strategy, highlighting strong Vyvgart uptake in gMG and CIDP and the recent U.S. approval of a self-injection... 
Via Stocktwits
Topics Earnings
News headline image
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble ↗
The company's drug treats two autoimmune conditions and recently launched with a prefilled synringe for at-home treatment. 
Via Investor's Business Daily
News headline image
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.